[1]张春雨 叶立果 王 龙 袁凡恩 彭泽生 陶 野 陈谦学 田道锋.胶质母细胞瘤驱动基因相关的竞争性内源RNA调控网络[J].中国临床神经外科杂志,2020,(09):607-609.[doi:10.13798/j.issn.1009-153X.2020.09.010]
 ZHANG Chun-yu,YE Li-guo,WANG Long,et al.Competing endogenous RNA regulatory network related to glioblastoma driver genes[J].,2020,(09):607-609.[doi:10.13798/j.issn.1009-153X.2020.09.010]
点击复制

胶质母细胞瘤驱动基因相关的竞争性内源RNA调控网络()
分享到:

《中国临床神经外科杂志》[ISSN:1009-153X/CN:42-1603/TN]

卷:
期数:
2020年09期
页码:
607-609
栏目:
论著
出版日期:
2020-09-20

文章信息/Info

Title:
Competing endogenous RNA regulatory network related to glioblastoma driver genes
文章编号:
1009-153X(2020)09-0607-03
作者:
张春雨 叶立果 王 龙 袁凡恩 彭泽生 陶 野 陈谦学 田道锋
430060 武汉,武汉大学人民医院神经外科(张春雨、叶立果、王 龙、袁凡恩、陶 野、陈谦学、田道锋);430010 武汉,长江航运总医院神经外科(彭泽生)
Author(s):
ZHANG Chun-yu1 YE Li-guo1 WANG Long1 YUAN Fan-en1 PENG Ze-sheng2 TAO Ye1 CHEN Qian-xue1 TIAN Dao-feng1.
1.Department of Neurosurgery, Renmin Hospital, Wuhan University, Wuhan 430060, China; 2. Department of Neurosurgery, Yangtze River Shipping General Hospital, Wuhan 430010, China
关键词:
胶质母细胞瘤竞争性内源RNA癌症基因组图谱生信分析
Keywords:
Glioblastoma Competing endogenous RNA Long non-coding RNA MicroRNA Bio-information analysis
分类号:
A
DOI:
10.13798/j.issn.1009-153X.2020.09.010
文献标志码:
R 739.41; Q 786
摘要:
目的 探讨胶质母细胞瘤(GBM)驱动基因相关的竞争性内源RNA(ceRNA)调控网络。方法 从癌症基因组图谱(TCGA)中下载169例GBM及5例正常组织长链非编码RNA(lncRNA)表达数据,从UCSC Xena数据库下载509例GBM及10例正常脑组织微小RNA(miRNA)表达数据。对获取的lncRNA及miRNA表达数据进行差异表达分析。GBM的17个驱动基因是从文献(PMID: 30096302)中获得。miRcode,TargetScan,miRTarBase和miRDB数据库预测lncRNA、miRNA和GBM驱动基因之间的相互作用。结果 GBM组织TP53及PTEN突变率最高,达30%,且TP53错义突变最常见。筛选出差异表达lncRNA共2 445个,表达上调1 052个,下调1 393个;差异表达miRNA共56 个,表达上调28个,下调28个。共有5 个GBM驱动基因、6 个miRNA 及297个lncRNA筛选出用于构建ceRNA网络,包括HOX转录反义RNA在内的8个lncRNA与GBM病人的生存相关。结论 采用生信分析方法构建ceRNA网络有助于深化GBM发生、发展机制的认识
Abstract:
Objective To explore the competing endogenous RNA (ceRNA) regulatory network related to glioblastoma driver genes. Methods The long non-coding RNA (lncRNA) expression data of 169 patients with glioblastoma and 5 normal brain tissues were downloaded from the Cancer Genome Atlas (TCGA), and the microRNA (miRNA) expression data of 509 patients with glioblastoma tissues and 10 normal brain tissues were downloaded from the UCSC Xena database. Differential expression analysis was performed on the lncRNA and miRNA expression data. The 17 driver genes of glioblastoma were obtained from the literature (PMID: 30096302). The miRcode, TargetScan, miRTarBase and miRDB databases were used to predict the interactions among lncRNA, miRNA and glioblastoma driver genes. Results The TP53 and PTEN mutation rates of glioblastoma tissues were the highest, which were up to 30%, and TP53 missense mutation was the most common. A total of 2 445 differentially expressed lncRNA was screened, with 1 052 up-regulation and 1 393 down-regulation. A total of 56 differentially expressed miRNA was screened, with 28 up-regulation and 28 down-regulation. A total of 5 driver genes of glioblastoma, 6 miRNA and 297 lncRNA was screened to construct the ceRNA network. Eight lncRNAs, including HOX transcrit antisense RNA, were related to the survival of glioblastoma patients. Conclusion The construction of ceRNA network with bio-information analysis method helps to further elucidate the mechanism of glioblastoma development

参考文献/References:

[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019 [J]. CA Cancer J Clin, 2019, 69(1): 7-34.
[2] 汪超甲,王 辉. 脑胶质瘤化疗现状及耐药机制的研究进 展[J]. 中国临床神经外科杂志,2017,22(11):791-794.
[3] Salmena L, Poliseno L, Tay Y, et al. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language [J]? Cell, 2011, 146(3): 353-358.
[4] Jeggari A, Marks DS, Larsson E. miRcode: a map of putative microRNA target sites in the long non-coding transcriptome [J]. Bioinformatics, 2012, 28(15): 2062-2063.
[5] Chou CH, Shrestha S, Yang CD, et al. miRTarBase update 2018: a resource for experimentally validated microRNA- target interactions [J]. Nucleic Acids Res, 2018, 46(D1): D296-302.
[6] Agarwal V, Bell GW, Nam JW, et al. Predicting effective microRNA target sites in mammalian mRNAs [J]. eLife, 2015, 4: e05005.
[7] Wong N, Wang X. miRDB: an online resource for microRNA target prediction and functional annotations [J]. Nucleic Acids Res, 2015, 43(Database issue): D146-152.
[8] Zhou X, Ren Y, Zhang J, et al. HOTAIR is a therapeutic target in glioblastoma [J]. Oncotarget, 2015, 6(10): 8353- 8365.
[9] Balasubramaniyan V, Bhat KP. Targeting MIR155HG in glioma: a novel approach [J]. Neuro Oncol, 2017, 19(9): 1152-1153.
[10] Wang J, Quan X, Peng D, et al. Long noncoding RNA DLEU1 promotes cell proliferation of glioblastoma multi- forme [J]. Mol Med Rep, 2019, 20(2): 1873-1882.

相似文献/References:

[1]谢宝树 张 林 王 宇 贾 锋 殷玉华.复发性多发胶质母细胞瘤的预后分析[J].中国临床神经外科杂志,2016,(06):333.[doi:10.13798/j.issn.1009-153X.2016.06.005]
 XIE Bao-shu,ZHANG Lin,WANG Yu,et al.Analysis of prognoses in patients with recurrent multiple glioblastomas[J].,2016,(09):333.[doi:10.13798/j.issn.1009-153X.2016.06.005]
[2]宋贵东 综述 高之宪 审校.贝伐单抗治疗复发胶质母细胞瘤的研究进展[J].中国临床神经外科杂志,2015,(10):638.[doi:10.13798/j.issn.1009-153X.2015.10.022]
[3]李继强 杨吉安 邵灵敏 吴庭枫 刘宝辉 陈谦学.稳定低表达BAG3的胶质母细胞瘤U87细胞株的构建及鉴定[J].中国临床神经外科杂志,2015,(06):353.[doi:10.13798/j.issn.1009-153X.2015.06.011]
 LI Ji-qiang,YANG Ji-an,SHAO Ling-min,et al.Construction and identification of U87 glioblastoma cell strain with a stable low expression of BAG3[J].,2015,(09):353.[doi:10.13798/j.issn.1009-153X.2015.06.011]
[4]桂志勇 冯 军 黄俊红 白敬洋.靶向沉默c-fos基因表达对胶质瘤U87MG细胞增殖与侵袭的影响[J].中国临床神经外科杂志,2017,(12):834.[doi:10.13798/j.issn.1009-153X.2017.12.011]
 GUI Zhi-yong,FENG Jun,HUANG Jun-hong,et al.Effects of c-fos targeted silence on proliferation and invasiveness of human glioma cell U87[J].,2017,(09):834.[doi:10.13798/j.issn.1009-153X.2017.12.011]
[5]王娇燕 孟凡华 刘魏然 魏春晓 林丽萍.SWI在胶质母细胞瘤与单发脑转移瘤鉴别中的价值[J].中国临床神经外科杂志,2018,(01):13.[doi:10.13798/j.issn.1009-153X.2018.01.005]
 WANG Jiao-yan,MENG Fan-hua,LIU Wei-ran,et al.Value of susceptibility-weighted imaging in differentiative diagnosis of glioblastomas and solitary brain metastases[J].,2018,(09):13.[doi:10.13798/j.issn.1009-153X.2018.01.005]
[6]张治元 王汉东 樊友武 贾 玥 吴晋蓉.胶质肉瘤15例分析及文献复习[J].中国临床神经外科杂志,2018,(02):69.
 ZHANG Zhi-yuan,WANG Han-dong,FAN You-wu,et al.Diagnosis and treatment of gliosarcoma: a report of 15 cases and literature review[J].,2018,(09):69.
[7]郑锐哲 姜秀峰 陈二涛 孙兆良 冯东福.胶质母细胞瘤卒中术后继发硬膜下水瘤1例[J].中国临床神经外科杂志,2019,(02):128.[doi:10.13798/j.issn.1009-153X.2019.02.022]
[8]胡 玥,薛小燕,李子超,等.阿苯达唑抑制胶质瘤裸鼠模型肿瘤生长[J].中国临床神经外科杂志,2019,(06):348.[doi:10.13798/j.issn.1009-153X.2019.06.010]
 HU Yue,XUE Xiao-yan,LI Zi-chao,et al.Albendazole inhibits tumor growth in nude mice model of glioma[J].,2019,(09):348.[doi:10.13798/j.issn.1009-153X.2019.06.010]
[9]殷安安 陆 南 贺亚龙 章 翔 刘玉河.TRIM38基因非CpG岛DNA甲基化与胶质母细胞瘤临床预后的关系[J].中国临床神经外科杂志,2020,(02):76.[doi:10.13798/j.issn.1009-153X.2020.02.005]
 YIN An-an,LU Nan,HE Ya-long,et al.Impacts of TRIM38 non-CpG island DNA methylation alterations on clinical prognosis in patients with glioblastomas[J].,2020,(09):76.[doi:10.13798/j.issn.1009-153X.2020.02.005]
[10]吴 蛟 易 勇 赵卓琳 周良学 周世军.贝伐珠单抗联合化疗治疗胶质母细胞瘤的meta分析[J].中国临床神经外科杂志,2020,(02):82.[doi:10.13798/j.issn.1009-153X.2020.02.007]
 WU Jiao,YI Yong,ZHAO Zhuo-lin,et al.Efficacy and safety of bevacizumab combined with chemotherapy for glioblastoma: a meta-analysis[J].,2020,(09):82.[doi:10.13798/j.issn.1009-153X.2020.02.007]

备注/Memo

备注/Memo:
(2019-11-09收稿,2020-05-01修回)基金项目:湖北省卫生和计划生育科学研究项目(WJ2017M019) 通讯作者:田道锋,E-mail:tiandaofeng@hotmail.com
更新日期/Last Update: 2020-09-20